Lymphoma clinical trials in Texas
45 studies for Lymphoma are looking for participants at sites in Texas.
Cities in Texas
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07015242A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Texas Oncology - Center South, Austin
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 15, 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Cook Children's Medical Center, Fort Worth
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Baylor College of Medicine, Houston
- Renovatio Clinical, The Woodlands
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06624085Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Houston
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07082803Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Renovatio Clinical - El Paso, El Paso
- Renovatio Clinical, The Woodlands
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06084936Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06218602Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- UT MD Anderson, Houston
RecruitingPhase 1
Ages 12 to 30 · All sexes · Updated Aug 12, 2026 · NCT07513129Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
- The University of Texas M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT05773040A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06563505A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT05929612A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05464719DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- MD Anderson, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT07465835A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0054), Dallas
RecruitingPhase 1/2
6 Months – 17 Years · All sexes · Updated Jul 6, 2026 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022CD4CAR for CD4+ Leukemia and Lymphoma
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jun 24, 2026 · NCT03829540A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Jun 10, 2026 · NCT02917083Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- MD Anderson Cancer Center, Houston
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio
Recruiting
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05676450Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT05011045Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- University of Texas Health Science Center at San Antonio, San Antonio
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
RecruitingPhase 1
All ages · All sexes · Updated Mar 2, 2026 · NCT01555892Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Mays Cancer Center at UT Health San Antonio, San Antonio
Recruiting
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT05745285From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.